Catalyst today announced it will be presenting at the JMP Securities 2014 Healthcare Conference, in New York. Senior Management will provide an overview of the Company and its key programs on Tuesday, June 24th at 12:30 pm ET. The Company’s presentation materials will be available on the “Investors” section of the Company’s website, www.catalystpharma.com following the presentation.

http://bit.ly/1qvkFLc

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst is set to join the Russell Microcap® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on Friday, June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $5.2 trillion in assets are benchmarked to the Russell Indexes.

http://bit.ly/1pi60RN

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst’s Chief Executive Officer Patrick J. McEnany will provide a company overview and program update at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5 at 2:00 pm ET.

http://bit.ly/1gDnLJv

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

“This year to date has been a very productive period, as we have built on the momentum established last year,” said Patrick J. McEnany, Catalyst’s Chief Executive Officer.  “Some of the highlights include significantly augmenting our financial position through an offering of common stock resulting in our current cash and investments position of about $47 million.” 

Mr. McEnany added, “We continue to advance our Firdapse™ program to treat LEMS towards registration, and, assuming our Phase 3 trial is successful, we remain on track to begin our planned NDA submission in early 2015.  At the same time, we are progressing a number of pre-commercial activities in preparation for the planned future launch of Firdapse™.  We believe that Catalyst is well positioned to attain our goal of providing innovative medicines to market to improve the lives of patients with neuromuscular and neurological disorders.”

Catalyst continues to expect top-line data from the double-blind portion of our pivotal Phase 3 trial for Firdapse™ in the third quarter of this year.  Over the next several months, assuming the Phase 3 trial is successful, Catalyst will prepare an NDA submission which it expects to begin filing in early 2015.  As a benefit of its Breakthrough Therapy Designation, the FDA has asked the Company to file the NDA in modules on a rolling basis in order to expedite the review and approval process.

Catalyst continues to progress CPP-115 towards initiation of a Phase 1 multiple ascending dose safety and tolerance study, which the Company expects to commence during the third quarter.

http://bit.ly/1nRxi26

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Exhibits at AAN

We are exhibiting this week at the 66th American Academy of Neurology (AAN) Annual Meeting– the largest gathering of neurologists and neuroscience professionals– at the Pennsylvania Convention Center in Philadelphia. Exhibit hours are Tuesday, April 29 – Thursday, May 1.

Print

Catalyst has begun the process required to establish an expanded access program (EAP) to make Firdapse available in the US to patients diagnosed with LEMS through their neuromuscular disease specialists.  The product, currently in Phase III development, will be provided at no cost until sometime after approval.  Program enrollment will begin in the next few months, pending FDA review and approvals.

Patrick McEnany, CEO of Catalyst said, “As part of our ongoing commitment to  the LEMS community, we are making Firdapse available to those who would like access to this investigational drug, but are unable to participate in clinical studies or to travel to sites where it is available.”

Patients diagnosed with LEMS or physicians treating such patients can call toll free 1-844-FIRDAPSE (1-844-347-3277) to inquire about this program.

http://bit.ly/1mDjgjT

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst today closed its previously announced public offering of shares of its common stock. Catalyst sold 13,023,750 shares, including 1,698,750 from the overallotment. Priced at $2.21 per share, the net proceeds from the sale of the shares is expected to be $26.8 million.

Piper Jaffray & Co. acted as the sole book-running manager for the offering, with Roth Capital Partners and H.C. Wainwright & Co., LLC acting as co-managers.

http://bit.ly/1hzw4ja

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

 

Leave a comment

Catalyst priced its public offering of 11,325,000 shares of its common stock at $2.21 per share. Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 1,698,750 shares of common stock to cover over-allotments, if any.

Net proceeds from the sale of the shares by Catalyst after expenses are expected to be approximately $23.3 million. Catalyst plans to use the net proceeds for:

  • Continuing development of Firdaps for the treatment for LEMS
  • Pre-commercialization activities relating to Firdapse
  • Continuing development of CPP-115
  • General corporate purposes

The offering is subject to customary closing conditions and is expected to close on April 8, 2014.

Piper Jaffray & Co. is acting as the sole book-running manager, Roth Capital Partners is acting as co-lead manager, and H.C. Wainwright & Co., LLC is acting as a co-manager with respect to this offering.

http://bit.ly/1ijC7uu

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

 

Leave a comment

Catalyst announced it intends to offer shares of its common stock in a public offering and to grant the underwriters a 30-day option to purchase additional shares to cover over-allotments, if any. Catalyst plans to use the net proceeds for:

  • Continuing development of Firdapse™ for the treatment for LEMS
  • Pre-commercialization activities relating to Firdapse™
  • Continuing development of CPP-115
  • General corporate purposes

Piper Jaffray & Co. is acting as the sole book-running manager. 

http://bit.ly/1mA4zLj

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst announced that it has reached the patient enrollment target of 36 patients for the double-blind, placebo-controlled, discontinuation portion of its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse for the symptomatic treatment of LEMS. The Company continues to screen additional, previously identified LEMS patients who have expressed interest in participating in this study. As allowed in the protocol for this study, all LEMS patients who are not randomized can continue to receive Firdapse as participants in the two-year follow-up period.

The company is on track to report top-line results in the third quarter of 2014.

http://bit.ly/1dNrkvo

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment
Follow

Get every new post delivered to your Inbox.

Join 201 other followers

%d bloggers like this: